



NCPDP Stakeholder Action Group on the Potential for Specialty Pharmacy Automation

April 5, 2016

NCPDP Office • Scottsdale, AZ

PRESENTERS



Lynnae Mahaney
Executive Director
Center for Pharmacy Practice
Accreditation (CPPA)



Tony Schueth
CEO & Managing Partner
Point-of-Care Partners



Laura Topor
President
Granada Health

SITUATION REVIEW / LEVEL SET

9:00 am – 10:00 am

• **Specialty Pharmacy Overview**

- Lynnae Mahaney
Executive Director, Center for Pharmacy Practice Accreditation (CPPA)

• **The “Problem” in Specialty Pharmacy**

- Tony Schueth
CEO & Managing Partner, Point-of-Care Partners

• **NCPDP Activities – Specialty Medication Related**

- Laura Topor
President, Granada Health

Specialty Pharmacy Overview

Lynnae Mahaney, BSPharm, MBA, FASHP



SPECIALTY PHARMACY in the HEALTHCARE MARKET

Healthcare costs and spending on medications 2014

- **2014 HC spending rate increases 5.3%**
- **2013 HC spending rate increase 2.9%**
- **Primary contributors?**
 - Coverage expansion (ACA)
 - Growth in prescription drug spending

SPECIALTY MEDICATIONS: A FORCE of HEALTH CARE

Medication Spending

- 2015 Rx meds 5.2% increase
- 2014 Rx meds 12.2% increase
- 2013 Rx meds 2.4% increase

Primary Contributors?

- New Active Substances
- Specialty medications
- Hep C treatments


Specialty medications are a growing and significant part of the nation's drug spend.

\$374 billion
in 2014
(IMS, April 2015)

\$12.3 billion
Hepatitis C

Health plans and PBMs can better monitor and control specialty drug spending through ePrescribing, electronic prior authorization and formulary data improvements.

Rise in Treatment Therapies



Express Scripts 2015 Drug Trend Report 20th Edition

IMS Institute for Healthcare Informatics; Medicines Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014; April 2015.


SPECIALTY DRUGS CONTINUE TO GROW

- In 2015, specialty medications accounted for 37.7% of total drug spending and a 17.8% overall trend, according to the annual Express Scripts Drug Trend Report. See more at: <http://www.specialtypharmacytimes.com/news/top-10-specialty-drug-therapeutic-classes#sthash.Q9qqC0of.dpuf>
- While the volume of specialty medications is less than 1% of total prescriptions, US spending on specialty drugs is projected to grow 67% by the end of 2015.
- Specialty medications are the fastest-growing sector in the American healthcare system, expected account for half of all drug costs by 2018.
- Specialty medications can run at \$2,000 per month per patient; those at the high-end cost upwards of \$100,000 to \$750,000 per year.

Specialty Med Spending:

67% growth
end 2015


Specialty Drugs as % of Total Drug Spend



Source: Prime Therapeutics

QUICK FACTS ON SPECIALTY PHARMACEUTICALS

- Cost per month generally ranges from \$2,500 to \$50,000.
- Two-thirds of new FDA approvals are for specialty drugs.
- 8 of the 10 top highest revenue drugs in 2016 will be specialty.
- Patients on these medications are complex, high-cost, and require regular follow-up.



CHALLENGES IN SPECIALTY PHARMACY

Multiple stakeholders:

- EHR and ePrescribing solution providers
- Pharmaceutical manufacturers
- HUB or other service providers
- Specialty pharmacy and pharmacy solution provider
- Payers

Multiple, bi-directional information needs among stakeholders

Information exchange relies on

- Paper
- Phone and fax

CHALLENGES IN SPECIALTY PHARMACY



Processes are:

- Cumbersome
- Incomplete
- Redundant
- Exceptionally inefficient
- **Barrier to optimal delivery of patient care**


The “Problem”

Tony Scheuth, CEO & Managing Partner, Point-of-Care Partners




POINT-OF-CARE PARTNERS
Health IT Management Consultants

TYPES OF SPECIALTY PRESCRIPTION TRANSACTIONS



REIMBURSEMENT HUB GOALS



Drill-down:

ePrescribing of Specialty Medications

REMS

ePrior Authorization

THE INFRASTRUCTURE IS IN PLACE



80%

Physicians Today

More than 80%
of physicians
ePrescribe today



700

EHRs Enabled

More than **700** EHRs
enabled for
ePrescribing



100%

Retail Pharmacies

Nearly **100%**
retail pharmacies

Developed for the **oral-solid, single molecule medications** traditionally dispensed in retail or mail service pharmacy.


Designed to accommodate **data elements the retail or mail pharmacy requires** (drug name, dosage, quantity and *sig*).

Insurance eligibility determined **before** patient arrives at physician's office.

Formulary and some benefit information is presented to prescriber before drug selection.

Pharmacy Directory provided by Surescripts to EHRs prior to prescribing.

CURRENT ePRESCRIBING FLOW



GAPS IN ePRESCRIBING THAT PERTAIN TO SPECIALTY



The prescriber doesn't know which pharmacies are part of the limited distribution or plan's network.

Data required to ultimately dispense a specialty medication is not included in the original prescription; in fact, SCRIPT may not even have the fields to accommodate.

There is no standard definition of specialty, so no specialty medications are flagged leading to specialty drugs being prescribed in the same manner as non-specialty.

The process requires coordination between the pharmacy and prescriber, and there are no transactions that facilitate status updates, and those that can be used for coordination may be sub-optimal.

Drill-down:

ePrescribing of Specialty Medications

REMS

ePrior Authorization

CHALLENGES WITH REMS

- Prescriber doesn't know if REMS is required ... or to what degree.
- Structured Product Label (SPL) is supposed to have REMS information. Compendia would, then, provide to EHRs/eRx companies. EHRs would have to purchase the module, and there are latency issues.
- Patient enrollment rarely in-office (generally given a brochure, and directed to visit a portal); practice generally doesn't have terminals for patients to enroll on-site.
- If not properly enrolled, claim will reject at POS.
- If REMS is educational, pharmacies have internal processes; however, if it's a lab, pharmacy must have results before dispensing.
- There are patient access challenges, especially after discharge.
- Reporting to FDA is challenging because of gaps in process and different formats.

Drill-down:

ePrescribing of Specialty Medications

REMS

ePrior Authorization

A LOOK AT THE ePA ROAD SO FAR

- 1996** HIPAA Passes, names 278 as standard for ePA
- 2003** MMA Passes
- 2004** Multi-SDO Task Group formed
- 2005** NCVHS Hearings
- 2006** MMA ePrescribing Pilots involving ePA
- 2007** Report to Congress recommending a new standard
- 2008** Expert Panel Formed/Roadmap Created
- 2009** Minnesota Law Passes New ePA Standard Created using SCRIPT
- 2011** CVS Caremark Pilot
- 2013** New Standard Published
- 2015** Implementation of SCRIPT-based Standard
- 2016** Expansion and EHR integration




NEW STANDARD ENABLES MULTIPLE WORKFLOWS

Retrospective vs. Prospective


Retrospective PA – Without PA info at time of prescribing



CURRENT LANDSCAPE



GAPS IN CURRENT PA ACTIVITIES

- 
- Drug requiring PA flagged in only 20% - 40% of the cases
 - Criteria not residing within EHR or visible to physician
 - Does not automate the entire process – various workarounds that may or may not meld together
 - Paper forms and portals require manual reentry of data that may already reside electronically within an EMR
 - Multiple routes to obtain PA depending on health plan, drug, pharmacy, and patient combination


NCPDP ACTIVITIES – SPECIALTY MEDICATION RELATED

Laura Topor, President, Granada Health

NCPDP EFFORTS

- **Electronic Prescribing**
- **Prior Authorization**
- **REMS**
- **Real Time Pharmacy Benefit Inquiry**
- **Reporting**

STANDARDS CONTINUUM



ELECTRONIC PRESCRIBING (eRx)

- **Added guidance to Recommendations Document to improve use of existing elements in SCRIPT 10.6**
 - Diagnosis
 - Height/Weight
 - Insurance Information
- **Added elements to SCRIPT Standard to support:**
 - e-prescribing of specialty medications
 - Agency and service information
 - IV administration
 - Patient information (i.e. hospice status, alternate contact)
 - Clinical information specific to wound care
 - Enhanced e-prescribing of compounded medications
- **Regulation to name new version of SCRIPT expected to be published November 2016**
 - Implementation anticipated in 2018

ELECTRONIC PRIOR AUTHORIZATION (ePA)

- ✦ **Included in NCPDP SCRIPT Standard**
- ✦ **First published in July 2013**
- ✦ **Supports prospective and retrospective models**
- ✦ **Allows for cancel and appeal functions**
- ✦ **Enhancements continue to be brought forth**
- ✦ **Guidance from industry implementation available in NCPDP's SCRIPT Implementation Recommendations Document**

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

- **FDA has authority to enforce these programs**
- **Industry needed a way to exchange information related to Elements to Assure Safe Use (ETASU) requirements**
- **FDA agreed to modifications to the Structured Product Label requirements so that REMS information could be supported by drug knowledge databases (compendia) and be readily available within EMRs**
- **NCPDP created new message types, modeled on ePA, and enhanced existing messages to support information exchange**
- **Regulation to name new version of SCRIPT expected to be published November 2016**
 - Messages from prescriber to REMS Administrator prior to sending prescription
 - Telecommunications Standard was modified to allow REMS processing to leverage claim adjudication process
- **The changes were initially approved by NCPDP members at the August 2015 Work Group meetings and will be published spring 2016**

REAL TIME PHARMACY BENEFIT INQUIRY (RTPBI)

- ✦ **Task Group investigating options to support a real time benefit check initiated by the prescriber**
- ✦ **Interest from ONC**
- ✦ **11 use cases have been identified, with associated data elements**
- ✦ **Further work includes analysis of technical options (EDI, XML, FHIR, etc.) and standard option (new, existing)**
- ✦ **Industry pilots underway; feedback will be shared with NCPDP**

REPORTING - SPECIALTY PHARMACY INITIATED

- **Specialty Pharmacy Data Exchange Sub-Task Group (within WG 7 - Manufacturer and Associated Trading Partner Transaction Standards)**
- **Develop standardized reporting to support contractual arrangements between the manufacturer and specialty pharmacy. There are four categories the group will address:**
 - **Order fulfillment**
 - Patient Census (Aggregate)
 - Performance Metrics/Case Management
 - Inventory
- **Current focus is to identify all needed data elements, then map to existing NCPDP data dictionary. If not in data dictionary, additions will be requested and the format will be presented to the membership for approval.**

The End



Lynnae Mahaney

608.444.7847

lmahaney@pharmacypracticeaccredit.org



Tony Schueth

954-346-1999

tonys@pocp.com



Laura Topor

952 938 6112

ltopormn@msn.com